간 질환 치료 시장 : 질환 유형별, 치료 유형별, 투여 경로별, 약제 클래스별, 최종사용자별, 유통 채널별 - 세계 예측(2026-2032년)

The Liver Diseases Therapeutics Market is projected to grow by USD 35.63 billion at a CAGR of 8.39% by 2032.

Liver diseases therapeutics is moving from symptom management toward disease modification, earlier intervention, and precision care across viral hepatitis, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), autoimmune liver disease, cholestatic disorders, cirrhosis, and hepatocellular carcinoma. The opportunity is substantial because liver disease remains a major global health burden: WHO reported 304 million people living with chronic hepatitis B or C in 2022, and viral hepatitis caused about 1.3 million deaths that year.

Demand is also being reshaped by obesity, type 2 diabetes, alcohol-related liver disease, and aging populations. MASLD is estimated to affect roughly one in three adults worldwide, creating a large pool of patients who may require noninvasive diagnostics, cardiometabolic co-management, antifibrotic treatment, and long-term monitoring. For industry leaders, progress will depend on evidence-rich pipelines, payer-ready outcomes data, scalable diagnostics, and integrated care models that connect hepatology, oncology, endocrinology, primary care, and digital health.

Transformative Shifts in the Landscape

The liver diseases therapeutics landscape is undergoing a structural shift as treatment innovation expands beyond antivirals into metabolic, immunologic, fibrotic, and oncology-driven mechanisms. Direct-acting antivirals transformed hepatitis C with cure rates commonly exceeding 95% in appropriate patients, while long-term hepatitis B strategies increasingly focus on functional cure approaches, including immune modulators, RNA-targeted therapies, and combination regimens.

In MASH, the field has entered a new era after the first U.S. FDA approval of a thyroid hormone receptor-beta agonist for adults with noncirrhotic MASH with moderate-to-advanced fibrosis. This milestone is accelerating investment in GLP-1-based metabolic therapies, FGF analogs, pan-PPAR agonists, FXR agonists, antifibrotics, and combination approaches. At the same time, liver cancer therapeutics continue to shift toward immunotherapy combinations, targeted agents, and biomarker-informed sequencing as hepatocellular carcinoma remains one of the leading causes of cancer death globally.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across liver diseases therapeutics by improving risk stratification, clinical trial design, imaging interpretation, and longitudinal disease monitoring. AI-enabled analysis of ultrasound, CT, MRI, elastography, pathology slides, laboratory patterns, and electronic health records can help identify patients with advanced fibrosis, cirrhosis decompensation risk, or hepatocellular carcinoma surveillance gaps earlier than conventional workflows.

For drug developers, AI supports target discovery, patient enrichment, synthetic control modeling, safety signal detection, and adaptive trial operations. In commercial care pathways, predictive analytics can prioritize hepatitis screening, MASLD referral, medication adherence, and transplant evaluation. The highest-value applications will be those validated across diverse populations, integrated into clinician workflows, and governed by transparent model performance, privacy protection, and regulatory-grade evidence.

Key Regional Insights

Asia-Pacific is a pivotal region for liver diseases therapeutics because of its large hepatitis B burden, rising diabetes and obesity rates, and expanding access to advanced diagnostics in China, Japan, South Korea, Australia, India, and ASEAN markets. Growth is increasingly tied to national hepatitis elimination plans, broader liver cancer surveillance, wider availability of noninvasive fibrosis testing, and local clinical trial capacity.

North America remains a leading innovation and reimbursement region, supported by specialty hepatology networks, advanced oncology care, transplant centers, and strong uptake potential for MASH therapies when supported by durable outcomes evidence. Europe benefits from structured health systems, guideline-driven screening, and established health technology assessment processes, although payer scrutiny requires robust cost-effectiveness and real-world evidence. Latin America, led by Brazil and Mexico, shows rising demand for hepatitis treatment, MASLD care, and cirrhosis management, but access variability persists across diagnostics, specialist referral, and reimbursement. The Middle East faces a dual burden of viral hepatitis and metabolic disease, with several health systems investing in prevention, diabetes management, and specialty liver care. Africa has high unmet need in hepatitis B diagnosis, birth-dose vaccination coverage, affordable antiviral access, liver cancer surveillance, and treatment infrastructure, making public health partnerships central to improved outcomes.

Key Group Insights

ASEAN markets are important for scalable hepatitis B management, hepatitis C elimination, and metabolic liver disease screening, especially as urbanization and diabetes prevalence rise across Southeast Asia. The GCC is emerging as a high-priority therapeutic environment because obesity, type 2 diabetes, and MASLD prevalence are elevated, while health systems are investing in specialty care, digital health, preventive screening, and chronic disease management programs.

The European Union is central to evidence-based reimbursement, health technology assessment, and harmonized clinical research, making real-world outcomes essential for access to MASH treatment, hepatitis therapeutics, and hepatocellular carcinoma therapy. BRICS countries combine large patient pools with expanding local manufacturing and clinical trial ecosystems, particularly in China, India, and Brazil, where hepatitis B, MASLD, and liver cancer burdens remain clinically significant. G7 markets continue to lead in specialty drug adoption, oncology innovation, precision diagnostics, and guideline-driven care pathways. NATO membership is not a healthcare market category, but many NATO countries overlap with high-income systems where liver cancer surveillance, MASH treatment, hepatitis elimination, and advanced cirrhosis care are increasingly prioritized.

Key Country Insights

The United States is a leading country for novel MASH therapeutics, hepatocellular carcinoma innovation, transplant hepatology, and high-value specialty care, while Canada emphasizes evidence-based access, public health screening, and integrated hepatitis strategies. Mexico and Brazil face growing MASLD and diabetes-related liver disease burdens, creating demand for affordable diagnostics, antiviral access, hepatology referral networks, and cirrhosis care pathways.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature hepatology infrastructure, strong clinical research participation, and guideline-based management of viral hepatitis, autoimmune liver disease, cholestatic disease, MASH, and liver cancer, while reimbursement decisions increasingly depend on fibrosis improvement, avoidance of decompensation, survival benefit, and quality-of-life evidence. Russia has ongoing demand for viral hepatitis and cirrhosis management, though access dynamics can vary by region and treatment category. China and India represent major clinical need due to hepatitis B, MASLD, diabetes, and liver cancer burdens, alongside expanding domestic research capacity and screening initiatives. Japan, South Korea, and Australia are advanced markets with strong surveillance systems, specialty care, noninvasive diagnostics, and readiness for precision therapeutics across chronic liver disease and hepatocellular carcinoma.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that demonstrate measurable clinical value, including fibrosis regression, reduced progression to cirrhosis, lower decompensation risk, improved survival in liver cancer, and patient-centered quality-of-life outcomes. In MASH, success will depend on pairing pharmacotherapy with noninvasive tests, cardiometabolic management, lifestyle support, and clear treatment algorithms for primary care and hepatology referral.

Organizations should invest in inclusive clinical trials that reflect real-world comorbidities, regional genotype patterns, metabolic risk profiles, alcohol use patterns, and diverse ethnic populations. Market access teams need early health economic models that quantify avoided transplant, hospitalization, cancer, decompensation, and productivity costs. Partnerships with diagnostic developers, AI platforms, payers, public health agencies, providers, and specialty pharmacies can improve screening, adherence, surveillance, and outcomes tracking across the liver disease continuum.

Research Methodology

This executive summary is based on a structured review of publicly available evidence from authoritative sources, including WHO, CDC, EASL, AASLD, IARC, national public health agencies, peer-reviewed hepatology journals, regulatory announcements, clinical guideline updates, and clinical development disclosures. Emphasis was placed on validated epidemiology, approved therapies, late-stage pipeline trends, disease burden indicators, and care delivery patterns.

Insights were synthesized through segmentation by disease area, treatment modality, geography, health system maturity, and access environment. Claims were limited to data-backed observations and widely recognized clinical or regulatory developments, with no reliance on market sizing, market share, or forecasting. The analysis prioritizes relevant themes such as liver diseases therapeutics, MASH treatment, hepatitis B therapeutics, hepatitis C antivirals, liver fibrosis, cirrhosis management, noninvasive liver diagnostics, and hepatocellular carcinoma therapy.

Conclusion

Liver diseases therapeutics is entering a more integrated and innovation-led phase, driven by the convergence of antivirals, metabolic therapies, antifibrotics, immuno-oncology, diagnostics, and artificial intelligence. The largest opportunities will come from earlier identification of at-risk patients, improved treatment persistence, effective surveillance, and therapies that demonstrate durable clinical outcomes rather than biomarker movement alone.

For stakeholders across biopharma, diagnostics, providers, payers, and public health systems, the strategic imperative is clear: build evidence-based, scalable, and equitable liver care models. Organizations that combine strong clinical differentiation with real-world evidence, regional access strategies, and digital-enabled care pathways will be best positioned to lead the next phase of advancement in liver diseases therapeutics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Liver Diseases Therapeutics Market, by Disease Type

• 7.1. Alcoholic Liver Disease
• 7.2. Hepatitis B
• 7.3. Hepatitis C
• 7.4. Liver Cancer
  • 7.4.1. Cholangiocarcinoma
  • 7.4.2. Hepatocellular Carcinoma
• 7.5. Non Alcoholic Lever Disease

8. Liver Diseases Therapeutics Market, by Therapy Type

• 8.1. Biologic Immunotherapies
• 8.2. Cell-Based & Regenerative Therapy
• 8.3. Gene Therapy
• 8.4. Microbiome-Modulating Therapies
• 8.5. Small-Molecule Drugs

9. Liver Diseases Therapeutics Market, by Route Of Administration

• 9.1. Intravenous
• 9.2. Oral
• 9.3. Subcutaneous

10. Liver Diseases Therapeutics Market, by Drug Class

• 10.1. Antifibrotic
  • 10.1.1. Pirfenidone
  • 10.1.2. Simtuzumab
• 10.2. Antivirals
  • 10.2.1. Interferons
  • 10.2.2. NS5A Inhibitors
  • 10.2.3. NS5B Polymerase Inhibitors
  • 10.2.4. Nucleotide/Nucleoside Analogues
  • 10.2.5. Protease Inhibitors
• 10.3. Chemotherapeutic
• 10.4. Corticosteroids
• 10.5. Immunosuppressants
• 10.6. Monoclonal Antibody

11. Liver Diseases Therapeutics Market, by End User

• 11.1. Clinic
• 11.2. Home Care Settings
• 11.3. Hospital

12. Liver Diseases Therapeutics Market, by Distribution Channel

• 12.1. Hospital Pharmacy
• 12.2. Online Pharmacy
• 12.3. Retail Pharmacy

13. Liver Diseases Therapeutics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Liver Diseases Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Liver Diseases Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Alnylam Pharmaceuticals, Inc.
• 17.3. Astellas Pharma Inc.
• 17.4. AstraZeneca PLC
• 17.5. Bristol-Myers Squibb Company
• 17.6. C. H. Boehringer Sohn AG & Co. KG
• 17.7. Eli Lilly and Company
• 17.8. F. Hoffmann-La Roche Ltd.
• 17.9. Genfit S.A.
• 17.10. Gilead Sciences, Inc.
• 17.11. GlaxoSmithKline plc
• 17.12. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
• 17.13. Johnson & Johnson Services Inc.
• 17.14. Merck & Co., Inc.
• 17.15. Moderna, Inc.
• 17.16. Novartis AG
• 17.17. Pfizer Inc.
• 17.18. Sanofi SA
• 17.19. Takeda Pharmaceutical Company Limited
• 17.20. Vertex Pharmaceuticals Incorporated